Summary: Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disrupters, and more in this webinar.
Summary: Learn about the complexities from raw material supply through drug product manufacturing, including planning early for a commercial-ready process.
Summary: This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps, and strategies and solutions to facilitate development through commercialization.
Summary: Learn about specific case studies for neuromuscular degenerative indications, AAV technology and manufacturing, strategies for navigating the current regulatory environments.
Summary: Learn about Catalent’s journey into the Cell and Gene therapy space, overcoming challenges, and the company’s commitment to its partners.
Summary: What hurdles need to be overcome before gene therapy is the new modality in the cancer therapy arsenal? We’ll look at manufacturing, viral vectors, and the most promising approaches coming to the clinic.
Summary: Catalent and LumaCyte experts collaborate to compare AAV production with three different transfection reagents.
Summary: To minimize off-line manipulations with aseptically-closed bioreactor system, iCELLis® Nano tubing assemblies were designed to use on-line bio-welding technology for each step from…
Summary: kLa estimations were performed for the iCELLis® Nano and iCELLis® 500 bioreactors with equivalent packed-bed size and compaction (4m2 and 500m2).
Summary: Gene therapy is a rapidly growing area in healthcare but, now the promise has been shown, we must focus on improving the manufacturing process and reducing…
Summary: Gene therapies have been exploding in popularity and lining up new programs looking to create a new standard of care models for a wide variety of diseases.